Cartesian Therapeutics, Inc. (RNAC)
10.17
+0.13
(+1.29%)
USD |
NASDAQ |
Aug 24, 16:00
10.17
0.00 (0.00%)
After-Hours: 20:00
Cartesian Therapeutics Debt to Equity Ratio : -0.5099 for June 30, 2026
Debt to Equity Ratio Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| June 30, 2026 | -0.5099 |
| March 31, 2026 | -0.08 |
| December 31, 2025 | -0.1004 |
| September 30, 2025 | -0.3516 |
| June 30, 2025 | -5.282 |
| March 31, 2025 | -0.6456 |
| September 30, 2024 | 19.48 |
| June 30, 2024 | -0.1465 |
| March 31, 2024 | -0.0895 |
| December 31, 2023 | -0.0764 |
| September 30, 2023 | 0.1737 |
| June 30, 2023 | 0.5335 |
| March 31, 2023 | 0.506 |
| December 31, 2022 | 0.4042 |
| September 30, 2022 | 0.4493 |
| June 30, 2022 | 0.3913 |
| March 31, 2022 | 0.6302 |
| December 31, 2021 | 1.567 |
| September 30, 2021 | -1.885 |
| June 30, 2021 | -8.371 |
| March 31, 2021 | -1.807 |
| Date | Value |
|---|---|
| December 31, 2020 | -1.963 |
| September 30, 2020 | -4.789 |
| June 30, 2020 | -2.038 |
| March 31, 2020 | -3.215 |
| December 31, 2019 | 2.296 |
| September 30, 2019 | -4.138 |
| June 30, 2019 | 404.16 |
| March 31, 2019 | 1.545 |
| December 31, 2018 | -3.947 |
| September 30, 2018 | 2.130 |
| June 30, 2018 | 0.8743 |
| March 31, 2018 | 0.5081 |
| December 31, 2017 | 0.4061 |
| September 30, 2017 | 0.322 |
| June 30, 2017 | 0.1323 |
| March 31, 2017 | 0.2771 |
| December 31, 2016 | 0.2192 |
| September 30, 2016 | 0.183 |
| June 30, 2016 | 0.1732 |
| March 31, 2016 | 0.8439 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| Allogene Therapeutics, Inc. | 0.1811 |
| Beam Therapeutics, Inc. | 0.2317 |
| C4 Therapeutics, Inc. | 0.2299 |
| Kyverna Therapeutics, Inc. | 0.1993 |
| Arrowhead Pharmaceuticals, Inc. | 2.956 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 318.63M |
| Total Liabilities (Quarterly) | 443.85M |
| Shareholders Equity (Quarterly) | -125.23M |
| Current Ratio | 7.475 |
| Net Debt Paydown Yield | -3.18% |